Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6117926 | International Journal of Antimicrobial Agents | 2014 | 4 Pages |
Abstract
We present a case of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis treated successfully with high-dose colistin- and tobramycin-impregnated bone cement as a drug delivery vehicle. For the first time, local colistin concentrations in drainage and synovial fluid were quantified in order to determine the optimal dose and to minimise serious side effects. Insertion of a bone cement spacer loaded with a high dose of tobramycin and colistin resulted in local colistin levels at the infection site that exceeded the minimum inhibitory concentration (MIC) of colistin against the isolated P. aeruginosa five-fold on Day 4. Thus, the treatment may be expected to exert a prolonged effect. Whereas systemic administration of colistin alone was not sufficient to treat the infection, combined local and parenteral therapy led to eradication of P. aeruginosa in this patient. Plasma colistin levels remained in the therapeutic range, which confirms the systemic safety of the method.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Jochen Krajewski, Stefanie M. Bode-Böger, Uwe Tröger, Jens Martens-Lobenhoffer, Thomas Mulrooney, Hagen Mittelstädt, Martin Russlies, Rainer Kirchner, Johannes K.-M. Knobloch,